Perennial Advisors LLC Has $4.38 Million Stake in Johnson & Johnson (JNJ)
Perennial Advisors LLC grew its stake in Johnson & Johnson (NYSE:JNJ) by 1.9% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 33,125 shares of the company’s stock after acquiring an additional 630 shares during the quarter. Johnson & Johnson accounts for 3.2% of Perennial Advisors LLC’s holdings, making the stock its 3rd biggest position. Perennial Advisors LLC’s holdings in Johnson & Johnson were worth $4,382,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds also recently made changes to their positions in the company. State Street Corp grew its position in shares of Johnson & Johnson by 4.3% in the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after purchasing an additional 6,656,371 shares during the period. Harbour Capital Advisors LLC grew its position in shares of Johnson & Johnson by 13,327.8% in the 2nd quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after purchasing an additional 2,482,843 shares during the period. Korea Investment CORP grew its position in shares of Johnson & Johnson by 38.9% in the 1st quarter. Korea Investment CORP now owns 2,130,033 shares of the company’s stock valued at $265,296,000 after purchasing an additional 596,134 shares during the period. Bank of Nova Scotia grew its position in shares of Johnson & Johnson by 94.5% in the 1st quarter. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock valued at $145,914,000 after purchasing an additional 569,313 shares during the period. Finally, Oppenheimer Asset Management Inc. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $65,598,000. 65.93% of the stock is owned by institutional investors.
Several brokerages recently issued reports on JNJ. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price objective for the company in a research report on Monday, October 30th. Citigroup Inc. boosted their price objective on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a research report on Thursday, October 19th. Jefferies Group LLC upped their price target on Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research report on Monday, October 16th. Finally, Barclays PLC upped their price target on Johnson & Johnson from $140.00 to $148.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 18th. Four investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and eleven have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $143.70.
Shares of Johnson & Johnson (JNJ) opened at $139.76 on Tuesday. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $144.35. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36. The firm has a market capitalization of $374,930.72, a price-to-earnings ratio of 19.55, a P/E/G ratio of 2.84 and a beta of 0.82.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion for the quarter, compared to analysts’ expectations of $19.29 billion. During the same quarter in the prior year, the business earned $1.68 EPS. The firm’s revenue for the quarter was up 10.3% on a year-over-year basis. equities analysts expect that Johnson & Johnson will post 7.28 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.40%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
WARNING: This piece was first reported by Daily Political and is owned by of Daily Political. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/14/perennial-advisors-llc-has-4-38-million-stake-in-johnson-johnson-jnj.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.